Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

teclistamab

(tek-LIS-tuh-mab)
A drug used to treat adults with multiple myeloma that came back or did not get better after treatment with at least four other anticancer therapies, including an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Teclistamab binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called BCMA, which is found on myeloma cells and some B cells (another type of white blood cell). This may help the immune system kill cancer cells. Teclistamab is a type of bispecific monoclonal antibody. Also called Tecvayli.
More Information
Search NCI's Dictionary of Cancer Terms